HK Stock Market Move | BIOCYTOGEN-B(02315) increased by more than 3%, licensing IDEAYA's dual-target ADC project IDE034 received FDA IND approval.

BIOCYTOGEN-B (02315) rose over 3%, up 2.84% as of the time of writing, at 31.86 Hong Kong dollars, with a turnover of 12.99 million Hong Kong dollars. On the news side, according to an announcement from BIOCYTOGEN-B's official WeChat account, on December 5th, the company announced that its partner, IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a company focused on the development of precision cancer therapeutics, has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application to advance their first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC) program into Phase I clinical trial. IDEAYA expects to begin patient enrollment in the first quarter of 2026 to evaluate solid tumor types co-expressing B7H3 and PTK7, including lung, colorectal, head and neck cancers, and ovarian/gynecologic tumors. Preclinical studies have shown that IDE034 as a single agent demonstrates deep and sustained tumor regression in multiple B7H3/PTK7-positive tumor models, indicating potent anti-cancer activity. Additionally, IDEAYA plans to explore a combination treatment strategy of IDE034 with their PARG inhibitor, IDE161, to enhance treatment durability, and intends to present more data supporting the mechanism of PARG and TOP1 ADC combination therapy at an important medical conference in the first half of 2026. The co-expression rate of B7H3/PTK7 in solid tumors such as lung, colorectal, and head and neck cancers is approximately 30%, 46%, and 27%, respectively, demonstrating its broad clinical potential.